Skip to content
Ramipril
Altace (ramipril) is a small molecule pharmaceutical. Ramipril was first approved as Altace on 1991-01-28. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA. The pharmaceutical is active against angiotensin-converting enzyme.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
endocrine system diseasesD004700
Trade Name
FDA
EMA
Altace (generic drugs available since 2005-10-24)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ramipril
Tradename
Company
Number
Date
Products
ALTACEKing PharmaceuticalsN-019901 RX1991-01-28
4 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
altaceNew Drug Application2020-06-10
ramiprilANDA2023-05-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
diabetic nephropathiesEFO_0000401D003928—
heart failureEFO_0003144D006333I50
hypertensionEFO_0000537D006973I10
left ventricular dysfunction—D018487—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C09: Agents acting on the renin-angiotensin system
— C09A: Ace inhibitors, plain
— C09AA: Ace inhibitors, plain
— C09AA05: Ramipril
— C09B: Ace inhibitors, combinations
— C09BA: Ace inhibitors and diuretics
— C09BA05: Ramipril and diuretics
— C09BB: Ace inhibitors and calcium channel blockers
— C09BB05: Ramipril and felodipine
— C09BB07: Ramipril and amlodipine
— C09BX: Ace inhibitors, other combinations in atc
— C09BX03: Ramipril, amlodipine and hydrochlorothiazide
— C09BX05: Ramipril and bisoprolol
— C10: Lipid modifying agents
— C10B: Lipid modifying agents, combinations
— C10BX: Lipid modifying agents in combination with other drugs
— C10BX04: Simvastatin, acetylsalicylic acid and ramipril
— C10BX06: Atorvastatin, acetylsalicylic acid and ramipril
— C10BX17: Rosuvastatin and ramipril
— C10BX18: Atorvastatin, amlodipine and ramipril
HCPCS
No data
Clinical
Clinical Trials
75 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sleep initiation and maintenance disordersD007319F51.01241512336
DeliriumD003693R41.0—1—517
Bipolar disorderD001714EFO_0000289F30.9——41—5
Sleep wake disordersD012893G47—1—113
SchizophreniaD012559EFO_0000692F20———2—2
Sleep deprivationD012892F51.12———112
Rem sleep behavior disorderD020187EFO_0007462G47.52———112
Migraine disordersD008881EFO_0003821G43—1—1—2
Chronobiology disordersD021081———112
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.9—1—1—2
Show 9 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Obstructive sleep apneaD020181EFO_0003918G47.33—11—13
AsthmaD001249EFO_0000270J45——1——1
Gastroesophageal refluxD005764EFO_0003948K21——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.1—1———1
Lung injuryD055370S27.30—1———1
Tobacco use disorderD014029F17—1———1
Delayed emergence from anesthesiaD055191—1———1
Neurocognitive disordersD019965F09—1———1
Migraine without auraD020326EFO_0005296G43.0—1———1
Migraine with auraD020325EFO_0005295G43.1—1———1
Circadian rhythm sleep disordersD020178G47.2—1———1
Substance-related disordersD019966EFO_0003890F13—1———1
BurnsD002056T30.0—1———1
Show 1 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Marijuana abuseD002189EFO_0007191F121————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinsonian disordersD020734HP_0001300————11
Healthy volunteers/patients—————11
NeuralgiaD009437EFO_0009430————11
Panic disorderD016584EFO_0004262F41.0————11
DementiaD003704F03————11
Huntington diseaseD006816G10————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRAMIPRIL
INNramipril
Description
Ramipril is a dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor, a prodrug, a cardioprotective agent, a matrix metalloproteinase inhibitor and a bradykinin receptor B2 agonist. It is a dicarboxylic acid monoester, an azabicycloalkane, a cyclopentapyrrole, a dipeptide and an ethyl ester.
Classification
Small molecule
Drug classantihypertensives (ACE inhibitors)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21
Identifiers
PDB—
CAS-ID87333-19-5
RxCUI35296
ChEMBL IDCHEMBL1168
ChEBI ID8774
PubChem CID5362129
DrugBankDB00178
UNII IDL35JN3I7SJ (ChemIDplus, GSRS)
Target
Agency Approved
ACE
ACE
Organism
Homo sapiens
Gene name
ACE
Gene synonyms
DCP, DCP1
NCBI Gene ID
1636
Protein name
angiotensin-converting enzyme
Protein synonyms
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1, carboxycathepsin, CD143, CD143 antigen, dipeptidyl carboxypeptidase 1, Dipeptidyl carboxypeptidase I, Kininase II, peptidase P
Uniprot ID
Q7M4L4
Mouse ortholog
Ace (11421)
angiotensin-converting enzyme (P09470)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 11,544 documents
View more details
Safety
Black-box Warning
Black-box warning for: Altace, Ramipril
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,447 adverse events reported
View more details